Join Growin Stock Community!

Revelation biosciences, inc.REVBW.US Overview

US StockHealthcare
(No presentation for REVBW)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

REVBW AI Insights

REVBW Overall Performance

REVBW AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

REVBW Recent Performance

-

Revelation biosciences, inc.

1.63%

Avg of Sector

0.63%

S&P500

REVBW PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

REVBW Key Information

REVBW Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

REVBW Profile

Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.

Price of REVBW

REVBW FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

REVBW Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.50
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.50
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is REVBW's latest earnings report released?

    The most recent financial report for Revelation biosciences, inc. (REVBW) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating REVBW's short-term business performance and financial health. For the latest updates on REVBW's earnings releases, visit this page regularly.

  • How much debt does REVBW have?

    As of the end of the reporting period, Revelation biosciences, inc. (REVBW) had total debt of 746.78M, with a debt ratio of 0.06. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does REVBW have?

    At the end of the period, Revelation biosciences, inc. (REVBW) held Total Cash and Cash Equivalents of 10.7B, accounting for 0.92 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is REVBW's EPS continuing to grow?

    According to the past four quarterly reports, Revelation biosciences, inc. (REVBW)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.65. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of REVBW?

    Revelation biosciences, inc. (REVBW)'s Free Cash Flow (FCF) for the period is -8.26B, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 221,438.58% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of REVBW?

    The latest valuation data shows Revelation biosciences, inc. (REVBW) has a Price-To-Earnings (PE) ratio of -1.98 and a Price/Earnings-To-Growth (PEG) ratio of 0.29. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.